GSK two-drug HIV combo finds success in key study

Jul 24, 2018

GlaxoSmithKline’s 3TC, an experimental two-drug combination of dolutegravir and lamivudine, is a treatment for HIV that was found to be as effective as standard triple therapy, even in people with relatively high levels of the virus that causes AIDS, in a recent clinical study.

GSK's researchers found found 91 percent of patients taking the combo had high levels of viral control versus 93 percent of those on three drugs in the 48-week study with 1,400 patients.

By simplifying to a two-drug treatment, GSK will compete with rivals by reducing potential side effects and reducing costs.

Read the Reuters report

Show Comments
Hide Comments

Join the discussion

We welcome your thoughtful comments.
All comments will display your user name.

Want to participate in the discussion?

Register for free

Log in for complete access.

Comments

No one has commented on this page yet.

RSS feed for comments on this page | RSS feed for all comments